Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a novel radiation pattern boost cervical cancer control?

NCT ID NCT07781475

Disease control Sponsor: The University of Hong Kong-Shenzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial investigates whether adding a special radiation technique called spatially fractionated radiation therapy (SFRT) to standard chemoradiation can improve outcomes for people with locally advanced cervical cancer. Participants with stage IIB to IVA disease will be randomly assigned to receive either standard treatment or standard treatment plus SFRT. The study aims to see if SFRT improves the chance of living without the cancer progressing for three years, while also checking safety and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Spatially fractionated radiation therapy (SFRT) added to standard chemoradiotherapy
What this could lead to
If successful, this approach could improve long-term control of locally advanced cervical cancer and potentially trigger immune responses that shrink tumors outside the radiation field.
What could go wrong
This is a randomized trial, but results are not yet available. SFRT may not improve outcomes over standard care, and radiation can cause side effects like fatigue, skin irritation, or damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 126 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Histologically confirmed cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. * FIGO 2018 stage IIB to IVA disease with primary tumor ≥4cm * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Planned to receive definitive chemoradiotherapy. * Able and willing to provide written informed consent. Exclusion Criteria: * Severe medical comorbidities that preclude the safe administration of radiotherapy. * Pregnancy or, for women of childbearing potential, inability to use effective contraception.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Hong Kong - Shenzhen Hospital,

    Shenzhen, Guangdong, 518053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.